Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | PHASE1 | RECRUITING | 604 | — | — | Sep 7, 2023 | Apr 30, 2027 | Jun 3, 2026 | 17 | United States |
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs, and vital signs
Number of participants with Dose Limiting Toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| RMC-9805 monotherapy arm | EXPERIMENTAL | Dose exploration and dose expansion |
| RMC-9805 plus RMC-6236 combination arm | EXPERIMENTAL | Dose exploration and dose expansion |
| Name | Type | Description |
|---|---|---|
| RMC-9805 | DRUG | Oral Tablets |
| RMC-6236 | DRUG | Oral Tablets |
Inclusion Criteria: * Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation * Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage * ECOG performance status 0 or 1 * Adequate ...